Results 1 to 10 of about 4,077,149 (265)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

BMC Cancer, 2022
Background Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported in advanced ...
Li Zhou, Xiaowen Wu, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xuan Wang, Xue Bai, Siming Li, Xiaoting Wei, Juan Li, Qing Yang, Jun Guo, Chuanliang Cui   +17 more
doaj   +1 more source

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy

Translational Oncology, 2021
Background: This study aimed to evaluate the effect of salvage therapy with nab-paclitaxel (nab-p) or temozolomide (TMZ) combined with antiangiogenic drugs in programmed death 1 (PD-1) inhibitor-resistant patients with unresectable metastatic melanoma ...
Xuan Wang, Weiran Xu, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Li Zhou, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xue Bai, Chuanliang Cui, Jun Guo   +13 more
doaj   +1 more source

Surgical Outcomes of Vaginal or Cervical Melanoma

Frontiers in Surgery, 2022
Objective: To evaluate the effectiveness of radical resection compared with non-radical resection for vaginal or cervical melanoma.Methods: We retrospectively analysed the clinical data of post-operative patients with primary lower genital tract melanoma
Hui Tian, Xuan Wang, Bin Lian, Lu Si, Min Gao, Hong Zheng, Zhihong Chi, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Jie Dai, Yangchun Sun, Lingying Wu, Jun Guo, Chuanliang Cui   +18 more
doaj   +1 more source

What do end-users want to know about managing the performance of healthcare delivery systems? Co-designing a context-specific and practice-relevant research agenda

Health Research Policy and Systems, 2021
Background Despite increasing interest in joint research priority-setting, few studies engage end-user groups in setting research priorities at the intersection of the healthcare and management disciplines.
Jenna M. Evans, Julie E. Gilbert, Jasmine Bacola, Victoria Hagens, Vicky Simanovski, Philip Holm, Rebecca Harvey, Peter G. Blake, Garth Matheson   +8 more
doaj   +1 more source

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy

Journal of Experimental & Clinical Cancer Research, 2019
Background Mucosal melanoma with poor prognosis is a common histopathologic subtype of melanoma among Chinese and other Asian peoples. Regulated microRNAs (miRNAs) have been reported as oncogenes or tumour suppressors in melanoma.
Huan Tang, Meng Ma, Jie Dai, Chuanliang Cui, Lu Si, Xinan Sheng, Zhihong Chi, Longwen Xu, Sifan Yu, Tianxiao Xu, Junya Yan, Huan Yu, Lu Yang, Yan Kong, Jun Guo   +14 more
doaj   +1 more source

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

EBioMedicine, 2020
Background: Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor. This study aimed to evaluate the tolerability, safety, pharmacokinetics and antitumor activities of vorolanib plus everolimus (an inhibitor of mammalian target of rapamycin).
Xinan Sheng, Xieqiao Yan, Zhihong Chi, Chuanliang Cui, Lu Si, Bixia Tang, Siming Li, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Lieming Ding, Li Mao, Jun Guo   +16 more
doaj   +1 more source

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Journal of Translational Medicine, 2017
Background Coexistence of enhancer of zeste homolog 2 (EZH2) and BRAF gene aberrations has been described in many cancer types. In this study, we aim to explore the coexistence status of BRAF V600E mutation and the copy number variation of EZH2 and ...
Huan Yu, Meng Ma, Junya Yan, Longwen Xu, Jiayi Yu, Jie Dai, Tianxiao Xu, Huan Tang, Xiaowen Wu, Siming Li, Bin Lian, Lili Mao, Zhihong Chi, Chuanliang Cui, Jun Guo, Yan Kong   +15 more
doaj   +1 more source

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort

Journal for ImmunoTherapy of Cancer, 2021
Background Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data ...
Xiaoling Yang, Keith Flaherty, Jun Guo, Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Genevieve Boland   +16 more
doaj   +1 more source

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Background Melanoma is one of the most aggressive cancers with extremely poor prognosis, and the median survival time for stage IV patients is approximately 6 to 8 months.
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation

Zhongliu Fangzhi Yanjiu, 2018
Objective To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation. Methods We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma (AM) or mucosal ...
WEI Xiaoting, BAI Xue, MAO Lili, CHI Zhihong, SHENG Xi'nan, CUI Chuanliang, WANG Xuan, LIAN Bin, TANG Bixia, YAN Xieqiao, LI Siming, ZHOU Li, GUO Jun, SI Lu   +13 more
doaj   +1 more source